Article
Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
Breast cancer research : BCR - 6 Jan 2016
de Groot Stefanie, Charehbili Ayoub, van Laarhoven Hanneke W M, Mooyaart Antien L, Dekker-Ensink N Geeske, van de Ven Saskia, Janssen Laura G M, Swen Jesse J, Smit Vincent T H B M, Heijns Joan B, Kessels Lonneke W, van der Straaten Tahar, Böhringer Stefan, Gelderblom Hans, van der Hoeven Jacobus J M, Guchelaar Henk-Jan, Pijl Hanno, Kroep Judith R
Abstract excerpt
BACKGROUND: The insulin-like growth factor 1 (IGF-1) pathway is involved in cell growth and proliferation and is associated with tumorigenesis and therapy resistance. This study aims to elucidate whether variation in the IGF-1 pathway is predictive for pathologic response in early HER2 negative breast cancer (BC) patients, taking part in the phase III NEOZOTAC trial, randomizing between 6 cycles of neoadjuvant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.